Megha Shah
Hematology & Oncology · Flemington, NJNPI 1437393352
Payments from drug & device makers
Across 393 payments — averaging $458.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$86K
- Beone Medicines Ltd.$45K
- Amgen$33K
- Daiichi Sankyo Inc.$3K
- AstraZeneca$3K
- Alnylam Pharmaceuticals Inc.$2K
- plus $8K from 54 others
What the payments were for
- Consulting fees$9,27055%
- Food & beverage$6,16237%
- Education$3582%
- Other$9976%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$180,041 in reported general payments places this provider in the 85th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $462,942 |
| ImbruvicaIbrutinib | 25 | $417,746 |
| LenvimaLenvatinib Mesylate | 15 | $363,397 |
| VerzenioAbemaciclib | 28 | $307,548 |
| VenclextaVenetoclax | 27 | $198,614 |
| NeulastaPegfilgrastim | 24 | $186,878 |
| RuxienceRituximab-Pvvr | 15 | $181,439 |
| ErleadaApalutamide | 12 | $179,142 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 13 | $170,640 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $162,384 |
| ProcritEpoetin Alfa | 41 | $144,607 |
| Neulasta OnproPegfilgrastim | 18 | $136,526 |
| Lupron DepotLeuprolide Acetate | 35 | $127,777 |
| LibtayoCemiplimab-Rwlc | 11 | $115,549 |
| Abiraterone Acetate | 20 | $89,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $160 | $462,94223 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $64 | $417,74625 claims |
| PfizerRuxience, Octagam, Eliquis | $233 | $370,19066 claims |
| Eisai Inc.Lenvima | $113 | $363,39715 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $568 | $340,39570 claims |
| AbbVieVenclexta, Lupron Depot | $190 | $326,39162 claims |
| Lilly USA, LLCVerzenio | $145 | $307,54828 claims |
| AmgenNeulasta | $32,618 | $186,87824 claims |
| Regeneron Healthcare Solutions, Inc.Libtayo | $175 | $115,54911 claims |
| Astellas Pharma US IncXtandi | $787 | $83,13411 claims |
| Heron Therapeutics, Inc.Cinvanti | $24 | $19,80438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Flemington
- Myron BednarFlemington$282K
- Waqas RehmanFlemington$150K
- Bruno FangEast Brunswick$8.5M
- Charles FarberMorristown$4.6M
- Rajat BannerjiNew Brunswick$3.3M
- Eleonora TeplinskyParamus$2.6M
- Mohamad CherryMorristown$1.9M
- Evan NaylorManahawkin$1.3M
- James OrsiniBelleville$1.3M
- Eli KirshnerWestwood$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.